학술논문
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Document Type
Article
Author
Tweed, Conor D ; Dawson, Rodney; Burger, Divan A; Conradie, Almari; Crook, Angela M; Mendel, Carl M; Conradie, Francesca; Diacon, Andreas H; Ntinginya, Nyanda E; Everitt, Daniel E; Haraka, Frederick; Li, Mengchun; van Niekerk, Christo H; Okwera, Alphonse; Rassool, Mohammed S; Reither, Klaus; Sebe, Modulakgotla A; Staples, Suzanne; Variava, Ebrahim; Spigelman, Melvin
Source
In The Lancet Respiratory Medicine December 2019 7(12):1048-1058
Subject
Language
ISSN
2213-2600